<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene E484Q literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.E484Q</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> >20% (ELISA significance threshold) drop in antibody binding by this variant against monoclonal antibody VH-Fc ab8.<br/> (<a href="https://doi.org/10.1101/2021.03.22.436481" class="lit_link">Sun et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at  later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b.<br/>Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104. Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113.<br/>Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32,  and no E484K immune escape at day 104.<br/>Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102. Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26,  and no E484K immune escape at day 102.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.02.003" class="lit_link">Greaney et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Bamlanivimab (LY-CoV555) lost ~20x binding against this isolated mutation.<br/>Casirivimab lost ~4x binding against this isolated mutation. (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant alone shows a 10x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. <br/> (<a href="https://doi.org/10.1101/2021.05.08.443253" class="lit_link">Ferriera et al (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
